Adaptimmune, after bringing cell therapy to market, questions viability and cuts 2 preclinical programs
Despite a historic FDA approval last year, Adaptimmune Therapeutics is expressing concerns about the longevity of the company and has resorted to cutting preclinical programs and evaluating strategic options.
Despite a historic FDA approval last year, Adaptimmune Therapeutics is expressing concerns about the longevity of the company and has resorted to cutting preclinical programs and evaluating strategic options.
